Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition

Biochimica et Biophysica Acta - General Subjects

Volumn 1820, Issue 4, 2012, Pages 503-510

  Pang, Tao ^a   Wang, Juan ^a   Benicky, Julius ^a   Saavedra, Juan M ^a  

^a DHHS   (United States)

Author keywords

Human monocytes; Inflammation; Lipopolysaccharide; LITAF; Minocycline; Nuclear receptor

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE INDUCED TUMOR NECROSIS FACTOR ALPHA FACTOR PROTEIN; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEAR RECEPTOR NUR77; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN KINASE B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOCYTE; NEUROLOGIC DISEASE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MINOCYCLINE; MONOCYTES; NF-KAPPA B; NUCLEAR PROTEINS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862811633     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.01.011     Document Type: Article

References (43)

1. V.H. Perry, T.A. Newman, and C. Cunningham The impact of systemic infection on the progression of neurodegenerative disease Nat. Rev. Neurosci. 4 2003 103 112 (Pubitemid 37271380)
2. W. Noble, C.J. Garwood, and D.P. Hanger Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding Prion 3 2009 78 83
3. D.P. Stirling, K.M. Koochesfahani, J.D. Steeves, and W. Tetzlaff Minocycline as a neuroprotective agent Neuroscientist 11 2005 308 322 (Pubitemid 41040860)
4. H.S. Kim, and Y.H. Suh Minocycline and neurodegenerative diseases Behav. Brain Res. 196 2009 168 179
5. A. Defaux, M.G. Zurich, P. Honegger, and F. Monnet-Tschudi Minocycline promotes remyelination in aggregating rat brain cell cultures after interferon-γ plus lipopolysaccharide-induced demyelination Neuroscience 187 2011 84 92
6. H. Zhou, B.M. Lapointe, S.R. Clark, L. Zbytnuik, and P. Kubes A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide J. Immunol. 177 2006 8103 8110 (Pubitemid 44846329)
7. J.H. Campbell, T.H. Burdo, P. Autissier, J.P. Bombardier, S.V. Westmoreland, C. Soulas, R.G. González, E.M. Ratai, and K.C. Williams Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS PLoS One 6 2011 e18688
8. K. Dutta, M.K. Mishra, A. Nazmi, K.L. Kumawat, and A. Basu Minocycline differentially modulates macrophage mediated peripheral immune response following Japanese encephalitis virus infection Immunobiology 215 2010 884 893
9. C.R. Dunston, H.R. Griffiths, P.A. Lambert, S. Staddon, and A.B. Vernallis Proteomic analysis of the anti-inflammatory action of minocycline Proteomics 11 2011 42 51
10. S. Ogura, A. Kakino, Y. Sato, Y. Fujita, S. Iwamoto, K. Otsui, R. Yoshimoto, and T. Sawamura Lox-1: the multifunctional receptor underlying cardiovascular dysfunction Circ. J. 73 2009 1993 1999
11. R.G. Baker, M.S. Hayden, and S. Ghosh NF-κB, inflammation, and metabolic disease Cell Metab. 13 2011 11 22
12. L. Pei, A. Castrillo, and P. Tontonoz Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77 Mol. Endocrinol. 20 2006 786 794
13. P.I. Bonta, C.M. van Tiel, M. Vos, T.W. Pols, J.V. van Thienen, V. Ferreira, E.K. Arkenbout, J. Seppen, C.A. Spek, T. van der Poll, H. Pannekoek, and C.J. de Vries Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses Arterioscler. Thromb. Vasc. Biol. 26 2006 2288 2294 (Pubitemid 44465724)
14. X. Tang, D.L. Marciano, S.E. Leeman, and S. Amar LPS induces the interaction of a transcription factor, LPS-induced TNF-alpha factor, and STAT6(B) with effects on multiple cytokines Proc. Natl. Acad. Sci. 102 2005 5132 5137
15. X. Tang, D. Metzger, S. Leeman, and S. Amar LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: evidence for LITAF-dependent LPS signaling pathways Proc. Natl. Acad. Sci. 103 2006 13777 13782 (Pubitemid 44413984)
16. S. Srinivasan, S.E. Leeman, and S. Amar Beneficial dysregulation of the time course of inflammatory mediators in lipopolysaccharide-induced tumor necrosis factor alpha factor-deficient mice Clin. Vaccine Immunol. 17 2010 699 704
17. F.Y. Ma, Y. Ikezumi, and D.J. Nikolic-Paterson Macrophage signaling pathways: a novel target in renal disease Semin. Nephrol. 30 2010 334 344
18. M. Guha, and N. Mackman The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells J. Biol. Chem. 277 2002 32124 32132 (Pubitemid 34969025)
19. J.P. Luyendyk, G.A. Schabbauer, M. Tencati, T. Holscher, R. Pawlinski, and N. Mackman Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages J. Immunol. 180 2008 4218 4226
20. G. Egidy, J. Friedman, M. Viswanathan, L.M. Wahl, and J.M. Saavedra CGP-42112 partially activates human monocytes and reduces their stimulation by lipopolysaccharides Am. J. Physiol. 273 1997 C826 C833
21. H.L. Li, J. Suzuki, E. Bayna, F.M. Zhang, E. Dalle Molle, A. Clark, R.L. Engler, and W.Y. Lew Lipopolysaccharide induces apoptosis in adult rat ventricular myocytes via cardiac AT(1) receptors Am. J. Physiol. Heart Circ. Physiol. 283 2002 H461 H467
22. E.A. Schwartz, W.Y. Zhang, S.K. Karnik, S. Borwege, V.R. Anand, P.S. Laine, Y. Su, and P.D. Reaven Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation Arterioscler. Thromb. Vasc. Biol. 30 2010 802 808
23. I.M. Larrayoz, T. Pang, J. Benicky, J. Pavel, E. Sánchez-Lemus, and J.M. Saavedra Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes J. Hypertens. 27 2009 2365 2376
24. M. Nagase, J. Abe, K. Takahashi, J. Ando, S. Hirose, and T. Fujita Genomic organization and regulation of expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) gene J. Biol. Chem. 273 1998 33702 33707 (Pubitemid 29005759)
25. Y. Shibata, N. Kume, H. Arai, K. Hayashida, A. Inui-Hayashida, M. Minami, E. Mukai, M. Toyohara, A. Harauma, T. Murayama, T. Kita, S. Hara, K. Kamei, and M. Yokode Mulberry leaf aqueous fractions inhibit TNF-alpha-induced nuclear factor kappaB (NF-kappaB) activation and lectin-like oxidized LDL receptor-1 (LOX-1) expression in vascular endothelial cells Atherosclerosis 193 2007 20 27 (Pubitemid 46776706)
26. R. Yoshimoto, Y. Fujita, A. Kakino, S. Iwamoto, T. Takaya, and T. Sawamura The discovery of LOX-1, its ligands and clinical significance Cardiovasc. Drugs Ther. 25 2011 379 391
27. O. Hofnagel, B. Luechtenborg, K. Stolle, S. Lorkowski, H. Eschert, G. Plenz, and H. Robenek Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells Arterioscler. Thromb. Vasc. Biol. 24 2004 1789 1795 (Pubitemid 39350293)
28. T. Navarra, S. Del Turco, S. Berti, and G. Basta The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications J. Atheroscler. Thromb. 17 2010 317 331
29. M. Nowicki, K. Müller, H. Serke, J. Kosacka, C. Vilser, A. Ricken, and K. Spanel-Borowski Oxidized low-density lipoprotein (oxLDL)-induced cell death in dorsal root ganglion cell cultures depends not on the lectin-like oxLDL receptor-1 but on the toll-like receptor-4 J. Neurosci. Res. 88 2010 403 412
30. B. You, Y.Y. Jiang, S. Chen, G. Yan, and J. Sun The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of IkappaBalpha expression Circ. Res. 104 2009 742 749
31. K.N. Bushell, S.E. Leeman, E. Gillespie, A.C. Gower, K.L. Reed, A.F. Stucchi, J.M. Becker, and S. Amar LITAF mediation of increased TNF-α secretion from inflamed colonic lamina propria macrophages PLoS One 6 2011 e25849
32. C.S. Piao, J.B. Kim, P.L. Han, and J.K. Lee Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult J. Neurosci. Res. 73 2003 537 544 (Pubitemid 36944846)
33. V. Muthusamy, and T.J. Piva The UV response of the skin: a review of the MAPK, NFkappaB and TNFalpha signal transduction pathways Arch. Dermatol. Res. 302 2010 5 17
34. J. Ishiyama, R. Taguchi, A. Yamamoto, and K. Murakami Palmitic acid enhances lectin-like oxidized LDL receptor (LOX-1) expression and promotes uptake of oxidized LDL in macrophage cells Atherosclerosis 209 2010 118 124
35. G. Schabbauer, M. Tencati, B. Pedersen, R. Pawlinski, and N. Mackman PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice Arterioscler. Thromb. Vasc. Biol. 24 2004 1963 1969 (Pubitemid 39350320)
36. U. Bommhardt, K.C. Chang, P.E. Swanson, T.H. Wagner, K.W. Tinsley, I.E. Karl, and R.S. Hotchkiss Akt decreases lymphocyte apoptosis and improves survival in sepsis J. Immunol. 172 2004 7583 7591 (Pubitemid 38747622)
37. S. Saivin, and G. Houin Clinical pharmacokinetics of doxycycline and minocycline Clin. Pharmacokinet. 15 1988 355 366 (Pubitemid 19012674)
38. Y. Lampl, M. Boaz, R. Gilad, M. Lorberboym, R. Dabby, A. Rapoport, M. Anca-Hershkowitz, and M. Sadeh Minocycline treatment in acute stroke: an open-label, evaluator-blinded study Neurology 69 2007 1404 1410 (Pubitemid 47511461)
39. S. Casha, D. Zygun, D. McGowan, V.W. Yong, and J.R. Hurlbert Neuroprotection with minocycline after spinal cord injury: results of a double blind, randomized, controlled pilot study Neurosurgery 65 2009 410 411
40. L.M. Metz, D. Li, A. Traboulsee, M.L. Myles, P. Duguette, J. Godin, M. Constantin, and V.W. Yong GA/minocycline study investigators, Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial Mult. Scler. 15 2009 1183 1194
41. P.H. Gordon, D.H. Moore, R.G. Miller, J.M. Florence, J.L. Verheijde, C. Doorish, J.F. Hilton, G.M. Spitalny, R.B. MacArthur, H. Mitsumoto, H.E. Neville, K. Boylan, T. Mozaffar, J.M. Belsh, J. Ravits, R.S. Bedlack, M.C. Graves, L.F. McCluskey, R.J. Barohn, R. Tandan Western ALS Study Group Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial Lancet Neurol. 6 2007 1045 1053 (Pubitemid 350116691)
42. NINDS NET-PD Investigators A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results Clin. Neuropharmacol. 31 2008 141 150
43. M. Thomas, T. Ashizawa, and J. Jankovic Minocycline in Huntington's disease: a pilot study Mov. Disord. 19 2004 692 695 (Pubitemid 39173025)